Japanese guidelines for childhood asthma 2020

• DOI: 10.1016/j.alit.2020.02.005
• Publication Date: 2020-04-25T01:31:49Z
• Authors: Hirokazu Arakawa; Yuichi Adachi; Motohiro Ebisawa; Takao Fujisawa; Hirokazu Arakawa; Yuichi Adachi; Motohiro Ebisaw; Takao Fujisawa; Akira Akasawa; Toshishige Inoue; Yukihiro Ohya; Makoto Kameda; Kazuyuki Kurihara; Naoki Shimojo; Yutaka Suehiro; Hiroyuki Mochizuki; Shigemi Yoshihara; Takashi Iwanaga; Haruo Kuroki; Masato Takase; Ikuyo Masuko; Kota Hirai; Koichi Yoshida; Yuzaburo Inoue; Mizuho Nagao; Yumiko Miyaji; Misa Iio; Yasunori Ito; Takumi Takizawa; Masaki Futamura; Junichiro Tezuka; Hironobu Fukuda; Yukinori Yoshida; Hajime Nishimoto; Tatsuki Fukuie; Sakura Sato; Yoshiyuki Yamada; Ikuo Okafuji; Kiwako Yamamoto-H...; Mari Sasaki; Yuya Tanaka; Yoichi Nakajima; Atsushi Isozaki; Eisuke Inage; Hisako Yagi; Mayu Shimizu; Kenichi Akashi; Norio Kawamoto; Tetsuharu Manabe; Hiroki Murai; Yuri Takaoka; Taro Miura; Yukiko Hiraguchi; Takeshi Sugiyama; Mayumi Sugimoto; Shuichi Suzuki; Osamu Natsume; Hiroshi Kitazawa; Akiko Yamaide; Takuya Wada; Sankei Nishima
• Keywords: Guideline; Asthma management

The Japanese Guideline for Childhood Asthma (JGCA) 2020 is a translation of the Pediatric Treatment and Management (JPGL) 2017 into English, which was published by Society Allergy Clinical Immunology. It makes recommendations best practices in management childhood asthma, including acute exacerbations non-pharmacological pharmacological management. These guidelines will be interest to non-specialist physicians involved care children with asthma. In JPGL, JPGL2017 first evidence-based updated according GRADE system Minds approach, it addresses eight clinical questions about treatment aged ≤5 years, infant preschool asthma diagnosed response short acting beta2 agonists or effect therapeutic trial during 1 month controller worsening after cessation. Long-term both promotes therapy measures against risk factors that induce exacerbation, better patient education partnership trinity. addition, long-term should not carried out without review but rather based on cycle evaluation, adjustment treatment. JPGL2017, transdermal patch oral are positioned as drugs within concept "short-term additional treatment" used until symptoms stabilized when control state transiently deteriorates.